NO20002049L - Hurtigoppløsende farmasøytisk preparat - Google Patents

Hurtigoppløsende farmasøytisk preparat

Info

Publication number
NO20002049L
NO20002049L NO20002049A NO20002049A NO20002049L NO 20002049 L NO20002049 L NO 20002049L NO 20002049 A NO20002049 A NO 20002049A NO 20002049 A NO20002049 A NO 20002049A NO 20002049 L NO20002049 L NO 20002049L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
fast dissolving
dissolving pharmaceutical
pharmaceutical composition
fast
Prior art date
Application number
NO20002049A
Other languages
English (en)
Other versions
NO319049B1 (no
NO20002049D0 (no
Inventor
Mamoru Ohashi
Kazuyoshi Ogasawara
Yoshimi Shirai
Hiroshi Fujioka
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of NO20002049D0 publication Critical patent/NO20002049D0/no
Publication of NO20002049L publication Critical patent/NO20002049L/no
Publication of NO319049B1 publication Critical patent/NO319049B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20002049A 1997-10-20 2000-04-18 Hurtigopplosende farmasoytisk preparat som omfatter mikronisert (R)-2-(4-brom-2-fluorbenzyl)-1,2,3,4-tetrahydropyrrol[1,2-a]pyrazin-4-spiro-3'-pyrrolidin-1,2',3,5'-tetron NO319049B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30663597 1997-10-20
PCT/JP1998/004658 WO1999020277A1 (en) 1997-10-20 1998-10-15 Rapidly soluble drug composition

Publications (3)

Publication Number Publication Date
NO20002049D0 NO20002049D0 (no) 2000-04-18
NO20002049L true NO20002049L (no) 2000-06-19
NO319049B1 NO319049B1 (no) 2005-06-06

Family

ID=17959478

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002049A NO319049B1 (no) 1997-10-20 2000-04-18 Hurtigopplosende farmasoytisk preparat som omfatter mikronisert (R)-2-(4-brom-2-fluorbenzyl)-1,2,3,4-tetrahydropyrrol[1,2-a]pyrazin-4-spiro-3'-pyrrolidin-1,2',3,5'-tetron

Country Status (21)

Country Link
US (2) US7141249B2 (no)
EP (1) EP1033132B1 (no)
KR (1) KR100571614B1 (no)
CN (1) CN1156277C (no)
AT (1) ATE296101T1 (no)
AU (1) AU740299B2 (no)
BR (1) BR9814090A (no)
CA (1) CA2306883C (no)
CZ (1) CZ299018B6 (no)
DE (1) DE69830333T2 (no)
ES (1) ES2242298T3 (no)
HU (1) HUP0004132A3 (no)
ID (1) ID23915A (no)
NO (1) NO319049B1 (no)
NZ (1) NZ503796A (no)
PL (1) PL191533B1 (no)
PT (1) PT1033132E (no)
RU (1) RU2203665C2 (no)
TR (1) TR200001056T2 (no)
TW (1) TW592728B (no)
WO (1) WO1999020277A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ503796A (en) * 1997-10-20 2001-11-30 Dainippon Pharmaceutical Co Fast-dissolving pharmaceutical composition comprising micronised (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201)
DK1884242T3 (da) 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
EP2327406A4 (en) * 2008-08-14 2014-04-09 Kyorin Seiyaku Kk STABILIZED PHARMACEUTICAL COMPOSITION
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK607188A (da) * 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
IE63463B1 (en) * 1989-02-06 1995-04-19 Zeneca Ltd Phenylsulphone derivatives
GB9016978D0 (en) * 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
TW202450B (no) 1991-06-26 1993-03-21 Dainippon Pharmaceutical Co
JPH0518672A (ja) * 1991-07-09 1993-01-26 Daido Steel Co Ltd 熱処理炉の冷却域における炉体構造
DE4141351A1 (de) * 1991-12-14 1993-06-17 Basf Ag Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung
DE4400464A1 (de) * 1994-01-11 1995-07-13 Bayer Ag Endoparasitizide Mittel
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
JP3995414B2 (ja) * 1997-10-20 2007-10-24 大日本住友製薬株式会社 安定な医薬組成物
NZ503796A (en) * 1997-10-20 2001-11-30 Dainippon Pharmaceutical Co Fast-dissolving pharmaceutical composition comprising micronised (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201)

Also Published As

Publication number Publication date
CN1282246A (zh) 2001-01-31
PT1033132E (pt) 2005-09-30
NO319049B1 (no) 2005-06-06
EP1033132B1 (en) 2005-05-25
EP1033132A8 (en) 2001-04-04
US20060269599A1 (en) 2006-11-30
WO1999020277A1 (en) 1999-04-29
NO20002049D0 (no) 2000-04-18
ID23915A (id) 2000-05-25
RU2203665C2 (ru) 2003-05-10
CA2306883C (en) 2007-11-27
CA2306883A1 (en) 1999-04-29
US7141249B2 (en) 2006-11-28
HUP0004132A3 (en) 2006-06-28
CN1156277C (zh) 2004-07-07
TW592728B (en) 2004-06-21
KR100571614B1 (ko) 2006-04-17
HK1030359A1 (en) 2001-05-04
BR9814090A (pt) 2000-10-03
DE69830333D1 (de) 2005-06-30
CZ299018B6 (cs) 2008-04-02
TR200001056T2 (tr) 2000-09-21
PL191533B1 (pl) 2006-06-30
DE69830333T2 (de) 2006-01-26
EP1033132A1 (en) 2000-09-06
ATE296101T1 (de) 2005-06-15
NZ503796A (en) 2001-11-30
KR20010015781A (ko) 2001-02-26
HUP0004132A2 (hu) 2001-08-28
PL340045A1 (en) 2001-01-15
CZ20001418A3 (cs) 2000-10-11
AU740299B2 (en) 2001-11-01
ES2242298T3 (es) 2005-11-01
US20020197308A1 (en) 2002-12-26
AU9461998A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
AU7102201A (en) Propane-1,3-dione derivatives
CA2319275A1 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
EP1659111A3 (en) Piperidine derivatives useful as ccr5 antagonists
CA2288122A1 (en) Neuropeptide y receptor antagonist
DE69841239D1 (de) Sequenzgenerierung, die eine Formulierung als Bedingungserfüllungsproblem nutzt
DE69833464D1 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
PT897904E (pt) 2-metoxibenzofenonas fungicidas
ATE364198T1 (de) 1,3-dihydro-1-oxo-2h-indenderivat
WO2003037864A1 (en) Indole compound and medicinal use thereof
EA199900935A1 (ru) Соединения индазоламида в качестве серотонинергических агентов
EP2269608A3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
AU6518998A (en) Morphinane derivatives and medicinal use thereof
CA2386813A1 (en) Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
DK1389213T3 (da) 3,7-Diazabicyclo[3.3.1]formuleringer som antiarytmiske forbindelser
ATE277901T1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
CA2356985A1 (en) 5ht1 antagonists for antidepressant therapy
NO20004273D0 (no) Streptograminderivater, deres fremstilling samt preparater inneholdende forbindelsene
NO20002049D0 (no) Hurtigoppløsende farmasøytisk preparat
WO2003097585A3 (en) Amidoacetonitrile compounds
EP1008345A4 (en) ANTI-ALLERGIC AGENTS
EP1132087A4 (en) REMEDIES FOR POLYKYSTIC OVARY SYNDROME
DK0896822T3 (da) 4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister
DE60023731D1 (de) Kunstharzzusammensetzungen, welche blauen farbstoff enthalten
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees